Brandon Tackett
Family Medicine · Atchison, KSNPI 1538506613
Payments from drug & device makers
Across 152 payments — averaging $16.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$479
- Lilly USA, LLC$326
- Amgen$200
- Pfizer$199
- Novo Nordisk$194
- GSK$116
- plus $925 from 25 others
What the payments were for
- Food & beverage$2,439100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 27 | $479 |
| Lilly USA, LLC | 20 | $326 |
| Amgen | 15 | $200 |
| Pfizer | 14 | $199 |
| Novo Nordisk | 12 | $194 |
| GSK | 9 | $116 |
| Abbott | 5 | $109 |
| AstraZeneca | 8 | $103 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $92 |
| Cequr Corporation | 1 | $75 |
| Sanofi-aventis U.S. LLC | 5 | $62 |
| Boehringer Ingelheim | 4 | $55 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $36 |
| Genentech USA, Inc. | 2 | $36 |
| Astellas Pharma US Inc | 2 | $35 |
| Biohaven Pharmaceuticals, Inc. | 2 | $34 |
| Novartis | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Eisai Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Merck | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Advanced Respiratory, Inc | 1 | $13 |
| Collegium Pharmaceutical, Inc. | 1 | $12 |
| Mylan Specialty L.p. | 1 | $12 |
How this compares
$2,439 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 66 | $79,081 |
| RybelsusSemaglutide | 25 | $38,620 |
| EliquisApixaban | 40 | $31,627 |
| OzempicSemaglutide | 24 | $31,522 |
| MounjaroTirzepatide | 14 | $14,775 |
| Spiriva RespimatTiotropium Bromide | 23 | $12,303 |
| OxycontinOxycodone Hcl | 12 | $11,971 |
| Spiriva HandihalerTiotropium Bromide | 11 | $9,422 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 173 | $5,500 |
| Buprenorphine | 14 | $2,896 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $2,783 |
| Dexlansoprazole DrDexlansoprazole | 13 | $2,573 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 11 | $2,466 |
| Humalog Kwikpen U-100Insulin Lispro | 13 | $1,847 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $1,676 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $55 | $91,38489 claims |
| Novo NordiskRybelsus, Ozempic | $194 | $70,14249 claims |
| PfizerEliquis | $199 | $31,62740 claims |
| Lilly USA, LLCMounjaro | $326 | $14,77514 claims |
| GSKShingrix | $116 | $2,46611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Atchison
- Terry PolingWichita$24.2M
- Richard GloverNewton$19.6M
- Daniel DickersonLenexa$13.6M
- Patrick YaoOlathe$11.7M
- Michael RauschAugusta$8.1M
- Terry KleinWichita$5.9M
- Richard EgelhofWichita$4.1M
- Thomas KleinWichita$3.4M
- Troy HoldemanNewton$3.2M
- Stacy SlechtaNewton$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.